News

31 Jul: ecancer catches up with Josep Tabernero on exploring new targets in GI cancer as well as the WIN Consortium launch of WINTHER, an original academic and international clinical trial

In two recent interviews with ecancer Josep Tabernero highlights key studies and promising data presented at the ESMO 14th World Congress on Gastrointestinal Cancer (WCGC), Barcelona, 27 – 30 June 2012, as well as discusses the WIN Consortium (Worldwide Innovative Networking in personalized cancer medicine) launch of WINTHER: The WIN therapeutics clinical trial.

06 Jun: ASCO Annual Meeting 2012: Largest study on women with breast cancer treated with PI3K inhibitors

ASCO Annual Meeting 2012: Largest study on women with breast cancer treated with PI3K inhibitors.

– The study was presented at the annual meeting of ASCO (American Society of Clinical Oncology) revealing findings surrounding the largest sample of breast cancer patients treated with this group of drugs.

– This research presented at ASCO was honored through a Merit Award from the Conquer Cancer Foundation — testament to its high quality and important scientific interest.

 

13 Mar: The New England Journal of Medicine coming to town: register now to attend the next VHIO Meet the Editors

VHIO Meet the Editors with The New England Journal of Medicine: Monday 14 May 2012

The New England Journal of Medicine´s Bette Phimister, Deputy Editor, will join us to deliver the next in the prestigious series of VHIO Meet the Editors talks:

Publishing Advances in Cancer Research

Bette Phimister will review progress and pitfalls in cancer research and issues concerning its publication, with a focus on targeted therapies and an eye to future developments.

28 Feb: A giant little step in cancer treatment opening up new therapeutic horizons

A study by the Vall d’Hebron Institute of Oncology (VHIO) demonstrates that by combining drugs which had already been used previously, but became ineffective, they boost each other’s efficacy and at the same time overcome the resistance developed by the patient to each individual drug. This strategy could offer an unprecedented key to multiplying treatment options.

Privacy Preferences
When you visit our website, it may store information through your browser from specific services, usually in form of cookies. Here you can change your privacy preferences. Please note that blocking some types of cookies may impact your experience on our website and the services we offer.